Eli Lilly (LLY) news

Older LLY news events, each with the realized, point-in-time move the market made — page 8 of 8. Back to the LLY overview → · Full LLY reaction history →

Latest news

Recent LLY events, each with its measured reaction. (Page 8 of 8.)

DateHeadlineEventSource5-minTo close
Form 8-K ELI LILLY & Co For: May 06SEC filing · Form 8-KSEC EDGAR-0.01%-1.92%
Lilly Declares Second-Quarter 2024 DividendPress releasePR Newswire-0.09%+2.13%
Form SD ELI LILLY & CoSEC filing · Form SDSEC EDGAR+0.52%+3.88%
Form 10-Q ELI LILLY & Co For: Mar 31SEC filing · Form 10-QSEC EDGAR-0.28%+0.91%
Form 8-K ELI LILLY & Co For: Apr 30SEC filing · Form 8-KSEC EDGAR+1.24%+1.05%
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline MomentumPress releasePR Newswire+1.24%+1.05%
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesityPress releasePR Newswire-0.13%-1.21%
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results AnnouncementPress releasePR Newswire+0.04%-0.40%
Form DEF 14A ELI LILLY & Co For: Mar 22SEC filing · Form DEFSEC EDGAR-0.18%+0.28%
Form DEFA14A ELI LILLY & CoSEC filing · Form DEFA14ASEC EDGAR-0.18%+0.28%
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab studyPress releasePR Newswire-1.73%-2.55%
Form PRE 14A ELI LILLY & Co For: Mar 08SEC filing · Form PRESEC EDGAR-1.73%-2.55%
U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of DonanemabPress releasePR Newswire-0.89%-1.79%
Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity CarePress releasePR Newswire+0.27%+0.94%
Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual MeetingPress releasePR Newswire-0.05%-0.45%
Form 10-K ELI LILLY & Co For: Dec 31SEC filing · Form 10-KSEC EDGAR+0.07%+0.37%
Lilly to Participate in Cowen's 44th Annual Health Care ConferencePress releasePR Newswire+0.09%-1.86%
Form 8-K ELI LILLY & Co For: Feb 07SEC filing · Form 8-KSEC EDGAR-0.14%+0.09%
Philip Johnson to Retire as Lilly TreasurerPress releasePR Newswire+0.52%+0.70%
Form 8-K ELI LILLY & Co For: Feb 06SEC filing · Form 8-KSEC EDGAR-1.69%-4.47%
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 GuidancePress releasePR Newswire-1.69%-4.47%
LILLY'S OLUMIANT® (BARICITINIB) NOW AUTHORIZED IN CANADA FOR ADULTS WITH SEVERE ALOPECIA AREATAPress releaseCanada Newswire-0.12%-0.00%
Johna Norton to Retire as Lilly Executive Vice President of Global QualityPress releasePR Newswire+0.23%+0.04%
Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial GuidancePress releasePR Newswire-0.11%+1.96%
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter MeetingPress releasePR Newswire-0.00%+0.55%
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy LasofoxifenePress releaseGlobeNewswire-0.14%+0.21%
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™Press releasePR Newswire-0.80%-2.00%
Lilly to Participate in J.P. Morgan Healthcare ConferencePress releasePR Newswire-0.14%+0.66%
Lilly Completes Acquisition of POINT BiopharmaPress releasePR Newswire+0.45%+1.93%
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023Press releasePR Newswire+0.25%+0.00%
Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeksPress releasePR Newswire-0.16%+0.34%
Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual MeetingPress releasePR Newswire+0.10%+0.47%
Lilly Announces 15% Dividend Increase, First-Quarter 2024 DividendPress releasePR Newswire+0.25%+2.11%
LILLY ANNOUNCES HEALTH CANADA'S AUTHORIZATION OF VERZENIO® (ABEMACICLIB) LABEL EXPANSIONPress releaseCanada Newswire-0.88%-0.00%
Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer SymposiumPress releasePR Newswire-0.36%+0.83%
Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with ObesityPress releasePR Newswire-0.36%+0.83%
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023Press releasePR Newswire+0.36%+0.61%
Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 InhibitorPress releasePR Newswire+0.36%+0.61%
Lilly Announces Plans to Open its First-ever Gateway Labs Site in San DiegoPress releasePR Newswire+0.28%-0.07%
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023Press releasePR Newswire-0.64%-0.13%
Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in GermanyPress releasePR Newswire-0.64%-0.13%
Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT BiopharmaPress releasePR Newswire-0.25%-3.65%
Lilly to Participate in Evercore ISI HealthCONx ConferencePress releasePR Newswire-0.64%-0.06%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground